Brief: Appili Therapeutics Announces Alignment With FDA On Development Requirements For Ati-1801 Topical Antiparasitic Product NDA Submission
31/10/2024 11:17
Oct 31 (Reuters) -
* APPILI THERAPEUTICS ANNOUNCES ALIGNMENT WITH FDA ON
DEVELOPMENT
REQUIREMENTS FOR ATI-1801 TOPICAL ANTIPARASITIC PRODUCT NDA
SUBMISSION
Source text: ID:nGNX4Fz408
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aditxt
See all newsBrief: Ignite Proteomics Announces 10,000-Patient Oncology Registry For Therapy Selection
Brief: Aditxt Appoints Jeffrey M. Busch As Interim CEO; Founder And Former CEO Of $1B NYSE Enterprise Which Delivered ~8.5% Dividends To Shareholders
NASDAQ TRADE HALT REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 03:28 AM